Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is also on track to finalize commercial manufacturing for the once weekly form of Byetta in the second half of 2008.

You may also be interested in...



Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta

Firms expect to file NDA by end of first half 2009.

Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta

Firms expect to file NDA by end of first half 2009.

Amylin Will Add Pancreatitis Cautions To Byetta Label

FDA issues Medwatch alert warning health care professionals of 30 cases of acute pancreatitis in patients taking the type 2 diabetes drug

Related Content

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel